인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Abstract Background Bedaquiline fumarate (BDQ) is an anti-tubercular Biopharmaceutics Classification System (BCS class-II) drug & it has very less solubility. Therefore, an effort has been made to prepare the bedaquiline fumarate co-crystal to improve its physicochemical and pharmaceutical characteristics. Results Using the solvent evaporation method, the drug bedaquiline fumarate and co-former ascorbic acid (AA) were co-crystallized. A series of analytical techniques, i.e., X-ray diffraction (XRD), Fourier transformation infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), scanning electron microscopy (SEM), and UV spectroscopy, etc., were used for the analysis of co-crystal to predict co-crystal formation by molecular docking. Micromeritic study and tablet formulation were done of bedaquiline fumarate and co-crystal formulation (1:2) batch. A permeability study was conducted on the chicken ileum. Conclusion Active pharmaceutical ingredients can co-crystallize with other small molecules or co-formers to create new solid dosage forms that have better physicochemical characteristics than pure drugs. 22 co-formers were screened with the drug, ascorbic acid was selected as a co-former because it has a binding energy of − 1.2 kcal/mol, two hydrogen bonds are formed, and it becomes readily soluble in water. This study indicated that ascorbic acid as a co-former can increase the dissolution profile of bedaquiline fumarate by the co-crystallization approach.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.